Logo image of CRIS

CURIS INC (CRIS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRIS - US2312693094 - Common Stock

1.05 USD
+0.01 (+0.96%)
Last: 12/24/2025, 8:22:35 PM
1.0616 USD
+0.01 (+1.1%)
After Hours: 12/24/2025, 8:22:35 PM
Fundamental Rating

2

Taking everything into account, CRIS scores 2 out of 10 in our fundamental rating. CRIS was compared to 530 industry peers in the Biotechnology industry. CRIS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CRIS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRIS has reported negative net income.
CRIS had a negative operating cash flow in the past year.
CRIS had negative earnings in each of the past 5 years.
CRIS had a negative operating cash flow in each of the past 5 years.
CRIS Yearly Net Income VS EBIT VS OCF VS FCFCRIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CRIS's Return On Assets of -132.25% is on the low side compared to the rest of the industry. CRIS is outperformed by 82.83% of its industry peers.
Industry RankSector Rank
ROA -132.25%
ROE N/A
ROIC N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRIS Yearly ROA, ROE, ROICCRIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

With an excellent Gross Margin value of 99.47%, CRIS belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
In the last couple of years the Gross Margin of CRIS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CRIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
CRIS Yearly Profit, Operating, Gross MarginsCRIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRIS has been increased compared to 1 year ago.
CRIS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRIS Yearly Shares OutstandingCRIS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRIS Yearly Total Debt VS Total AssetsCRIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -67.90, we must say that CRIS is in the distress zone and has some risk of bankruptcy.
CRIS has a Altman-Z score of -67.90. This is amonst the worse of the industry: CRIS underperforms 94.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -67.9
ROIC/WACCN/A
WACC8.82%
CRIS Yearly LT Debt VS Equity VS FCFCRIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.70 indicates that CRIS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.70, CRIS is doing worse than 90.38% of the companies in the same industry.
A Quick Ratio of 0.70 indicates that CRIS may have some problems paying its short term obligations.
CRIS's Quick ratio of 0.70 is on the low side compared to the rest of the industry. CRIS is outperformed by 90.19% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.7
CRIS Yearly Current Assets VS Current LiabilitesCRIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.01% over the past year.
The Revenue has grown by 13.56% in the past year. This is quite good.
Measured over the past years, CRIS shows a small growth in Revenue. The Revenue has been growing by 1.75% on average per year.
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%

3.2 Future

The Earnings Per Share is expected to grow by 14.21% on average over the next years. This is quite good.
Based on estimates for the next years, CRIS will show a very strong growth in Revenue. The Revenue will grow by 57.54% on average per year.
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRIS Yearly Revenue VS EstimatesCRIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
CRIS Yearly EPS VS EstimatesCRIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CRIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRIS Price Earnings VS Forward Price EarningsCRIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIS Per share dataCRIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as CRIS's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.9%
EPS Next 3Y22.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRIS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CURIS INC

NASDAQ:CRIS (12/24/2025, 8:22:35 PM)

After market: 1.0616 +0.01 (+1.1%)

1.05

+0.01 (+0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners35.77%
Inst Owner Change7.62%
Ins Owners6.98%
Ins Owner Change0%
Market Cap13.58M
Revenue(TTM)11.65M
Net Income(TTM)-36.56M
Analysts81.82
Price Target14.28 (1260%)
Short Float %0.89%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.99%
Min EPS beat(2)16.89%
Max EPS beat(2)25.09%
EPS beat(4)3
Avg EPS beat(4)12.17%
Min EPS beat(4)-3.2%
Max EPS beat(4)25.09%
EPS beat(8)5
Avg EPS beat(8)-0.2%
EPS beat(12)8
Avg EPS beat(12)0.44%
EPS beat(16)9
Avg EPS beat(16)-0.26%
Revenue beat(2)2
Avg Revenue beat(2)5.5%
Min Revenue beat(2)2.12%
Max Revenue beat(2)8.88%
Revenue beat(4)3
Avg Revenue beat(4)15.4%
Min Revenue beat(4)-10.12%
Max Revenue beat(4)60.74%
Revenue beat(8)5
Avg Revenue beat(8)10.15%
Revenue beat(12)6
Avg Revenue beat(12)4.79%
Revenue beat(16)7
Avg Revenue beat(16)1.63%
PT rev (1m)-3.45%
PT rev (3m)-14.29%
EPS NQ rev (1m)-1.81%
EPS NQ rev (3m)3.43%
EPS NY rev (1m)1.85%
EPS NY rev (3m)9.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.14%
Revenue NY rev (1m)3.32%
Revenue NY rev (3m)3.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.67
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS0.9
BVpS-1.14
TBVpS-1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.47%
FCFM N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.7
Altman-Z -67.9
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%
EBIT growth 1Y28.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.88%
EBIT Next 3Y-18.99%
EBIT Next 5Y1.48%
FCF growth 1Y25.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.74%
OCF growth 3YN/A
OCF growth 5YN/A

CURIS INC / CRIS FAQ

What is the fundamental rating for CRIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRIS.


Can you provide the valuation status for CURIS INC?

ChartMill assigns a valuation rating of 1 / 10 to CURIS INC (CRIS). This can be considered as Overvalued.


How profitable is CURIS INC (CRIS) stock?

CURIS INC (CRIS) has a profitability rating of 1 / 10.


What is the financial health of CURIS INC (CRIS) stock?

The financial health rating of CURIS INC (CRIS) is 0 / 10.